US OptionsDetailed Quotes
ACXP241220P4000
- 0.00
- 0.000.00%
15min DelayTrading Nov 26 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest4.00Strike Price0.00Turnover0.00%IV-274.18%PremiumDec 20, 2024Expiry Date2.93Intrinsic Value100Multiplier24DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma0.35Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Acurx Pharmaceuticals Stock Discussion
💰 BTC ETFs : $774.6M 📈
💰 ETH ETFs : -$30M 📉
⚡Elon Musk and Vivek Ramaswamy to launch "Dogecast" podcast for the #DOGE Department of Government Efficiency.
💰 BlackRock and Fidelity's spot #Bitcoin ETFs did a combined $4.17 BILLION in trading volume today
🔥 Biopharmaceutical company Acurx Pharmaceuticals is buying up to $1 million in #Bitcoin💰 as a treasury reserve asset
⚡️Bitwise registers for its #Solana💰 ETF in Delaware, per state d...
Acurx Announces Additional Ibezapolstat Ph2b Results in CDI as well as Anthrax (B. anthracis) Susceptibility to ACX-375 Analogues
Acurx Pharmaceuticals (NASDAQ: ACXP)announced new analyses extending data on ibezapolstat's beneficial effects on the gut microbiome for C. difficile Infection (CDI) treatment. The data showed increased beneficial bacteria, reversing dysbiosis and contributing to CDI anti-recurrence. Ibezapolstat's favorable pharmacokinetics were c...
Acurx Announces Additional Ibezapolstat Ph2B Results in Cdi as Well as Anthrax (B. Anthracis) Susceptibility to Acx-375 Analogues
Acurx Announces Results of Its Pioneering Research with Ibezapolstat in Collaboration with Leiden University Medical Center at the Premier International C. difficile Symposium
Acurx Pharmaceuticals (NASDAQ: ACXP) announced results from its research on ibezapolstat in collaboration with Leiden University Medical Center (LUMC) at the International C. difficile Symposium. The research revealed high-resolution details of ibezapolstat's interaction with its mole...
oIn September 2024, the World Antimicrobial Resistance conference in Philadelphia;oIn September 2024,...
Uspto Grants Acurx Pharmaceuticals New Patent for Ibezapolstat to Treat Cdi While Reducing Recurrence of Infection and Improving Health of the Gut Microbiome
USPTO Grants Acurx Pharmaceuticals New Patent for Ibezapolstat to Treat CDI While Reducing Recurrence of Infection and Improving Health of the Gut Microbiome
Acurx Pharmaceuticals (NASDAQ: ACXP) has been granted a new patent by the USPTO for ibezapolstat, its treatment for C. difficile Infection (CDI). The patent, issued on July 16, 2024, covers ibezapolstat's ability to treat CDI while reducing infection recurrence and improving gut microbiome health. This p...
No comment yet